Top Markets
#1 Black Phoenix Black Phoenix +355.71%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.01%
#4 Gold Park Gold Park +55.15%
#5 Acurast Acurast +28.90%
#6 BasedHype BasedHype +28.38%
#7 Cryptopia Cryptopia +22.67%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#9 Avantis Avantis +16.65%
#10 HOME HOME +15.01%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
株式のランク #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
株価
$0.0127
最終同期: 2026-08-12
時価総額
$66.48K
変化（1日）
-2.31%
変化（1年）
-67.44%
国
US
取引 Vincerx Pharma, Inc. (VINC)

カテゴリー

Healthcare
Vincerx Pharma, Inc.（VINC）の利益
2026 時点の利益 TTM: 0
Vincerx Pharma, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Vincerx Pharma, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE